Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

In today’s episode, we had the pleasure of speaking with Eunice Wang, MD, about the secondary AML treatment paradigm. Dr Wang is a professor of oncology, leader of the Leukemia Clinical Disease Team, chief of leukemia in the Department of Medicine, and an assistant member of the Tumor Immunology Program in the Department of Immunology at Roswell Park Comprehensive Cancer Center in Buffalo, New York; as well as an associate professor in the Department of Medicine and an academic scholar at the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo.

In our exclusive interview, Dr Wang discussed the prevalence of secondary AML, and explained that this population lacks standard therapies, often relying on allogeneic stem cell transplantation. She noted that CPX-351, a liposomal formulation of cytarabine and daunorubicin, has generated improved outcomes compared with 7+3 chemotherapy in this population. She also highlighted future research, which includes targeted therapies and less intensive regimens.